{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:15:07Z","timestamp":1789179307283,"version":"build-2803163510"},"reference-count":41,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJNS"],"abstract":"<jats:p>Newborn screening (NBS) for mucopolysaccharidosis type I (MPS I, Hurler syndrome) is currently conducted in about two-fifths of the NBS programs in the United States and in a few other countries. Screening is performed by measurement of residual activity of the enzyme alpha-l-iduronidase in dried blood spots using either tandem mass spectrometry or digital microfluidic fluorometry (DMF). In this article, we focus on the development and practical experience of using DMF to screen for MPS I in the USA. By means of their responses to a questionnaire, we determined for each responding program that is screening for MPS I using DMF the screen positive rate, follow-up methods, and classification of confirmed cases as either severe or attenuated. Overall, the results show that at the time of reporting, over 1.3 million newborns in the US were screened for MPS I using DMF, 2094 (0.173%) of whom were screen positive. Of these, severe MPS I was confirmed in five cases, attenuated MPS I was confirmed in two cases, and undetermined phenotype was reported in one case. We conclude that DMF is an effective and economical method to screen for MPS I and recommend second-tier testing owing to high screen positive rates. Preliminary results of NBS for MPS II and MPS III using DMF are discussed.<\/jats:p>","DOI":"10.3390\/ijns6040078","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T10:19:23Z","timestamp":1602238763000},"page":"78","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Digital Microfluidics in Newborn Screening for Mucopolysaccharidoses: A Progress Report"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0150-5185","authenticated-orcid":false,"given":"Jon","family":"Washburn","sequence":"first","affiliation":[{"name":"Baebies, Inc., Durham, NC 27709, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Millington","sequence":"additional","affiliation":[{"name":"Duke University Hospital Biochemical Genetics Lab, Durham, NC 27709, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/clinchem\/47.4.780","article-title":"Diagnosis of \u03b1-L-iduronidase deficiency in dried blood spots on filter paper: The possibility of newborn diagnosis","volume":"47","author":"Chamoles","year":"2001","journal-title":"Clin. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cccn.2004.04.009","article-title":"Glycogen storage disease type II: Enzymatic screening in dried blood spots on filter paper","volume":"347","author":"Chamoles","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1373\/clinchem.2003.028381","article-title":"Tandem Mass Spectrometry for the Direct Assay of Enzymes in Dried Blood Spots: Application to Newborn Screening for Krabbe Disease","volume":"50","author":"Li","year":"2004","journal-title":"Clin. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2004.035907","article-title":"Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening","volume":"50","author":"Li","year":"2004","journal-title":"Clin. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1373\/clinchem.2004.047167","article-title":"Tandem mass spectrometric analysis of dried blood spots for screening of mucopolysaccharidosis I in newborns","volume":"51","author":"Wang","year":"2005","journal-title":"Clin. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1373\/clinchem.2009.141622","article-title":"Newborn Screening of Lysosomal Storage Disorders","volume":"56","author":"Marsden","year":"2010","journal-title":"Clin. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ajmg.c.30291","article-title":"Newborn screening for lysosomal storage disorders","volume":"157","author":"Nakamura","year":"2011","journal-title":"Am. J. Med. Genet. Part C Semin. Med. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-anchem-062011-143028","article-title":"Digital Microfluidics","volume":"5","author":"Choi","year":"2012","journal-title":"Annu. Rev. Anal. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1586\/erm.11.22","article-title":"Applications of electrowetting-based digital microfluidics in clinical diagnostics","volume":"11","author":"Pollack","year":"2011","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/j.semperi.2009.12.008","article-title":"Digital Microfluidics: A Future Technology in the Newborn Screening Laboratory?","volume":"34","author":"Millington","year":"2010","journal-title":"Semin. Perinatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1373\/clinchem.2011.163139","article-title":"Digital microfluidic platform for multiplexing enzyme assays: Implications for lysosomal storage disease screening in newborns","volume":"57","author":"Sista","year":"2011","journal-title":"Clin. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.ymgme.2011.11.038","article-title":"A pilot newborn screening program for lysosomal storage disorders (LSD) in Illinois","volume":"105","author":"Burton","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cca.2013.05.001","article-title":"Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform","volume":"424","author":"Sista","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1542\/peds.2005-2633I","article-title":"Newborn Screening: Toward a Uniform Screening Panel and System\u2014Executive Summary","volume":"117","author":"Watson","year":"2006","journal-title":"Pediatrics"},{"key":"ref_15","unstructured":"Advisory Committee on Heritable Disorders in Newborns and Children (2020, September 10). Official Web Site of the U.S. Health Resources & Services Administration, Available online: https:\/\/www.hrsa.gov\/advisory-committees\/heritable-disorders\/index.html."},{"key":"ref_16","unstructured":"(2020, September 10). FDA Permits Marketing of First Newborn Screening System for Detection of Four, Rare Metabolic Disorders; FDA: Montgomery and Prince Georges Counties, MD, USA, 2017, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-marketing-first-newborn-screening-system-detection-four-rare-metabolic-disorders."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","article-title":"Lysosomal storage disorder screening implementation: Findings from the first six months of full population pilot testing in Missouri","volume":"166","author":"Hopkins","year":"2015","journal-title":"J. Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamapediatrics.2018.0263","article-title":"Incidence of 4 lysosomal storage disorders from 4 years of newborn screening","volume":"172","author":"Hopkins","year":"2018","journal-title":"JAMA Pediatr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/14737159.2018.1495076","article-title":"Digital microfluidics comes of age: High-throughput screening to bedside diagnostic testing for genetic disorders in newborns","volume":"18","author":"Millington","year":"2018","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijns4030024","article-title":"Current State of the Art of Newborn Screening for Lysosomal Storage Disorders","volume":"4","author":"Millington","year":"2018","journal-title":"Int. J. Neonatal Screen."},{"key":"ref_21","unstructured":"Martin, J.A., Brady, M.P.H., Hamilton, E., Ventura, S.J., Michelle, M.A., Osterman, J.K., Wilson, E.C., and Mathews, T.J. (2010). National Vital Statistics Reports Births: Final Data for 2010, National Center for Biotechnology Information."},{"key":"ref_22","unstructured":"Kemper, A.R., Brosco, J., Comeau, A.M., Green, N.S., Prosser, L.A., Ojodu, J., Tanksley, S., Jones, E., and Lam, K.K. (2015). Newborn Screening for Mucopolysaccharidosis Type 1 (MPS I): A Systematic Review of Evidence Report of Final Findings Final Version 1.1 The Condition Review Workgroup, Association of Public Health Laboratories."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ymgme.2012.09.024","article-title":"Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and III","volume":"107","author":"Wagemans","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/ijns6030069","article-title":"Evaluation of Multiple Methods for Quantification of Glycosaminoglycan Biomarkers in Newborn Dried Blood Spots from Patients with Severe and Attenuated Mucopolysaccharidosis-I","volume":"6","author":"Herbst","year":"2020","journal-title":"Int. J. Neonatal Screen."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/ijns6030072","article-title":"Current Practices for U.S. Newborn Screening of Pompe Disease and MPSI","volume":"6","author":"Ames","year":"2020","journal-title":"Int. J. Neonatal Screen."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","article-title":"Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience","volume":"190","author":"Burton","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jpeds.2019.04.027","article-title":"The North Carolina Experience with Mucopolysaccharidosis Type I Newborn Screening","volume":"211","author":"Taylor","year":"2019","journal-title":"J. Pediatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jpeds.2018.09.063","article-title":"Taiwan national newborn screening program by tandem mass spectrometry for mucopolysaccharidoses types I, II, and VI","volume":"205","author":"Chan","year":"2019","journal-title":"J. Pediatr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-018-0816-4","article-title":"Status of newborn screening and follow up investigations for Mucopolysaccharidoses I and II in Taiwan","volume":"13","author":"Chuang","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/ijns4040041","article-title":"Performance of the Four-Plex Tandem Mass Spectrometry Lysosomal Storage Disease Newborn Screening Test: The Necessity of Adding a 2nd Tier Test for Pompe Disease","volume":"4","author":"Chiang","year":"2018","journal-title":"Int. J. Neonatal Screen."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijns5020024","article-title":"Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy","volume":"5","author":"Burlina","year":"2019","journal-title":"Int. J. Neonatal Screen."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jpeds.2016.11.036","article-title":"Mucopolysaccharidosis Type I Newborn Screening: Best Practices for Diagnosis and Management","volume":"182","author":"Clarke","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13052-018-0552-3","article-title":"Newborn screening in mucopolysaccharidoses","volume":"44","author":"Donati","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/mas.21463","article-title":"Expanded newborn screening by mass spectrometry: New tests, future perspectives","volume":"35","author":"Ombrone","year":"2016","journal-title":"Mass Spectrom. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/gim.2017.194","article-title":"Precision newborn screening for lysosomal disorders","volume":"20","author":"Stoway","year":"2018","journal-title":"Genet. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sanders, K.A., Gavrilov, D.K., Oglesbee, D., Raymond, K.M., Tortorelli, S., Hopwood, J.J., Lorey, F., Majumdar, R., Kroll, C.A., and McDonald, A.M. (2020). A comparative effectiveness study of newborn screening methods for four lysosomal storage disorders. Int. J. Neonatal Screen., 6.","DOI":"10.3390\/ijns6020044"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijns6010020","article-title":"Post-Analytical Tools for the Triage of Newborn Screening Results in Follow-up Can Reduce Confirmatory Testing and Guide Performance Improvement","volume":"6","author":"Hall","year":"2020","journal-title":"Int. J. Neonatal Screen."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jpeds.2019.07.053","article-title":"Population-Based Newborn Screening for Mucopolysaccharidosis Type II in Illinois: The First Year Experience","volume":"214","author":"Burton","year":"2019","journal-title":"J. Pediatr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ymgme.2011.12.011","article-title":"A novel fluorometric enzyme analysis method for Hunter syndrome using dried blood spots","volume":"105","author":"Tolun","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Singh, R., Chopra, S., Norton, S., and Pamula, V. (2020, October 05). Demonstration of a Digital Microfluidic Platform for the High Throughput Analysis of 12 Discrete Fluorimetric Enzyme Assays Using a Single Newborn Dried Blood Spot Punch. Available online: https:\/\/worldsymposia.org\/wp-content\/uploads\/WORLDSymposium-2018-Poster-List.pdf.","DOI":"10.1016\/j.ymgme.2017.12.361"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/diagnostics10010021","article-title":"Digital Microfluidic Platform to Maximize Diagnostic Tests with Low Sample Volumes from Newborns and Pediatric Patients","volume":"10","author":"Sista","year":"2020","journal-title":"Diagnostics"}],"container-title":["International Journal of Neonatal Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2409-515X\/6\/4\/78\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:17:29Z","timestamp":1760177849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2409-515X\/6\/4\/78"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["ijns6040078"],"URL":"https:\/\/doi.org\/10.3390\/ijns6040078","relation":{},"ISSN":["2409-515X"],"issn-type":[{"value":"2409-515X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]}}}